“They’re pretty advanced down the path” of doing a deal, according to one source who has direct knowledge of the talks between the two companies. “It’s going to be more of the ‘recovery drink’ category,” the source added.
The move has wide-ranging implications because it recognizes the conflict between law and medicine. The proposal cites marijuana’s known medicinal properties and how existing EU prohibitions on cannabis prevent the scientific community from implementing research and treatment, particularly in a widely fractured legal regulatory environment.
NHS figures show the total for 2017-18 was £1.3bn, which is 25.7% more expensive than 10 years ago.
“The use of natural-occurring cannabinoids as a therapy for companion animals is a logical new forefront of medical discovery and the research we are working on at CAH is world leading. These trial approvals mark a significant milestone on the journey of making cannabis-based drugs accepted and recommended by veterinarians.”
“Hemp saved our business,” he said. “This year we earned 10 times more than what we used to earn with wheat and it has enabled us to hire four workers.”